Caladrius Biosciences to Present at Zooming with LD
July 22 2021 - 8:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse disease,
today announced that its President and CEO, David J. Mazzo, PhD,
will be presenting virtually at the Zooming with LD event on
Thursday, July 29, 2021, at 10:00am Pacific Time/1:00pm Eastern
Time. The presentation will be webcast live via the link below on
the Investors & News section of the Company’s website
https://ir.caladrius.com.
Webcast Link: Zooming with LD: Caladrius
Zooming with LD allows companies to tap one of the largest
investor communities in the micro-cap space and is by invite only.
For more information on the event, please contact your LD Micro
institutional sales representative.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study (www.freedom-trial.com) in the U.S.
for the treatment of coronary microvascular dysfunction (“CMD”);
CLBS12 (HONEDRA® in Japan), recipient of orphan designation
for Buerger’s Disease in the U.S. as well as SAKIGAKE
designation and eligible for early conditional approval in Japan
for the treatment of critical limb ischemia (“CLI”) and Buerger’s
Disease based on the results of an ongoing clinical trial; CLBS201,
designed to assess the safety and efficacy of CD34+ cell therapy as
a treatment for diabetic kidney disease (“DKD”); and OLOGO™
(CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”)
designated therapy for which the Company is in discussion with the
FDA to finalize a Phase 3 protocol of reduced size and scope for a
confirmatory trial in subjects with no-option refractory disabling
angina (“NORDA”). For more information on the Company, please
visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryRachel GirardReal ChemistryPhone:
401-477-4030Email: rgirard@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024